Featured Content
The FDA has approved Novartis’ Rhapsido (remibrutinib) for adults with symptomatic dermographism whose symptoms are inadequately controlled with H1 antihistamines.…
The FDA has approved Novartis’ Rhapsido (remibrutinib) for adults with symptomatic dermographism whose symptoms are inadequately controlled with H1 antihistamines.…